Oncology

Latest News

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 4th 2015

FDA Announces Measure to Ease Patient Access to Investigational Drugs

In his blog post on FDAVoice, Peter Lurie MD, MPH, associate FDA commissioner for public health strategy and analysis, announced the introduction of a draft form and a draft guideline that can be used by a physician to request access to an experimental drug or biological product that is still under development.

February 4th 2015

IOM Report Addresses Responsible Sharing of Clinical Trial Data

The report, according to ASCO, delineates responsibilities of different stakeholders towards ensuring responsible data sharing of trial results.

February 3rd 2015

Palbociclib Approved for Post-Menopausal Women With Advanced Breast Cancer

The efficacy of the CDK4/6 inhibitor was demonstrated in 165 postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous treatment for advanced disease.

February 3rd 2015

Study Compares Adjuvant Radiotherapy With Observation in Low-Risk DCIS

The study, published in the Journal of Clinical Oncology concluded that the failure rate was low with observation but was decreased significantly with the addition of radiotherapy.

February 3rd 2015

"Methylome" Could Distinguish Aggressive Triple-Negative Breast Cancer

The study identified distinct methylation patterns between the aggressive and benign forms of TNBC, which could provide an improved understanding of disease outcome.

February 3rd 2015

Cost-Effectiveness Decisions: Who Do You Trust?

A study published in the Journal of Thoracic Disease digs deep into understanding the assumptions in HEOR studies that evaluate the cost-effectiveness of personalized cancer treatments.

Panel Discussion: The Road to Personalized Medicine: Clinical Utility and Reimbursement in Molecular Diagnostics

February 3rd 2015

Panel Discussion: The Road to Personalized Medicine: Clinical Utility and Reimbursement in Molecular Diagnostics

Panelists discuss ways to improve the focus on clinical utility in molecular diagnostics given challenges in the system and needs of patients.

February 2nd 2015

Study Substantiates Cost-Effectiveness of Biomarker-Based NSCLC Treatment

Multiplexed genetic screening for EGFR and ALK gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic NSCLC setting in the United States, researchers report in The Journal of Thoracic Oncology.

February 2nd 2015

Genentech's Anti-PD-L1 Agent Receives Breakthrough Status in Advanced NSCLC

With 3 I-O agents have already been approved for metastatic melanoma, 2 from BMS and 1 from Merck, the race for NSCLC has tightened with multiple ongoing clinical trials.

January 30th 2015

Dendreon Sees Light at the End of the Provenge Tunnel

The Canadian company Valeant Pharmaceuticals International Inc has reached an agreement to buy the prostate cancer immunotherapy from Dendreon Corp.

January 30th 2015

Precision Oncology Clinical Service Partnership Announced

The integrated cancer services offered by Sarah Cannon will soon be supported by the personalized medicine technology platform of Syapse, to improve individualized patient care, the companies have announced.

Dr Howard K. Kaufman on the Need for More Diverse Populations in Clinical Trials

January 30th 2015

Dr Howard K. Kaufman on the Need for More Diverse Populations in Clinical Trials

Clinical trials are critical for pushing the oncology field forward, but there is a need for not only more patients to participate in clinical trials, but for a more diverse population, said Howard K. Kaufman, MD, FACS.

The Role of mHealth in Oncology

January 29th 2015

The Role of mHealth in Oncology

Mobile health (mHealth) can be so much more than smartphone apps, and it is a growing movement in the United States that can empower patients, providers, and payers, according to Meg Maley, RN, BSN, founder and CEO of CanSurround.

January 29th 2015

Imbruvica Approved for Waldenstrom's Macroglobulinemia

The drug, jointly developed by Pharmacyclics and Janssen Biotech, has received prior approvals for 3 other indications.

January 29th 2015

Smoking Promotes Disease Progression in Prostate Cancer, Study Reports

Smokers diagnosed with prostate cancer who were treated with radiation were at a greater risk of their cancer returning, metastasizing, and ultimately causing death. Former smokers, however, did not have the increased risk.

January 29th 2015

Eli Lilly Expects Multiple Stakeholders Will Benefit from CII, a PACE Initiative

PACE has launched an evidence-based online tool, Continuous Online Indicators, which will provide information on research progress in 12 tumor types.

Segment 11: Two Paradigms Being Presented in Medical Oncology

January 28th 2015

Segment 11: Two Paradigms Being Presented in Medical Oncology

Daniel F. Hayes, MD, outlines the 2 paradigms presented in medical oncology: one where people would rather be overtreated rather than miss a chance to benefit by being undertreated and another where a person might not be willing to do something until they learn there is a reason to do so.

Segment 10: The Important Distinction Between Diagnostic, Screening Tests

January 28th 2015

Segment 10: The Important Distinction Between Diagnostic, Screening Tests

There is an important distinction between diagnostic and screening tests, and they have different issues in regards to decision making-although the person making treatment decisions should ultimately be guiding the ship, according to Bryan Loy, MD, MBA.

Segment 9: Who Should Order the Test?

January 28th 2015

Segment 9: Who Should Order the Test?

Both Francisco J. Esteva, MD, PhD, and Daniel F. Hayes, MD, agree that the role of genetic counselors should be limited when order diagnostic tests in medical oncology.

Segment 7: Guidelines for Diagnostic Test Use

January 28th 2015

Segment 7: Guidelines for Diagnostic Test Use

The panelists discuss guidelines for diagnostic test use and the biggest challenge from a payer standpoint.

Segment 6: Learning About CancerLinQ as It Rolls Out

January 28th 2015

Segment 6: Learning About CancerLinQ as It Rolls Out

Daniel Hayes, MD, explains the implementation of the American Society of Clinical Oncology's CancerLinQ for beta testing.

Segment 5: Proper Use of Tests

January 28th 2015

Segment 5: Proper Use of Tests

Bryan Loy, MD, MBA, discusses how payers can measure diagnostic test use and results, and Daniel Hayes, MD, weighs in with how CancerLinQ from the American Society of Clinical Oncology can help.

Segment 4: The FDA Takes Initiative to Regulate the Diagnostic Test Market

January 28th 2015

Segment 4: The FDA Takes Initiative to Regulate the Diagnostic Test Market

Daniel F. Hayes, MD, discusses the FDA's announcement that it will begin to regulate laboratory-developed tests and his belief that it will not squash innovation in the field.

January 28th 2015

Amgen-Onyx File for Full Approval for Kyprolis in MM

Kyprlois is currently approval for use in multiple myeloma patients who have progressed on 2 prior therapies.

Dr Yousuf Zafar Explains How Financial Toxicity Impacts Cancer Patients

January 28th 2015

Dr Yousuf Zafar Explains How Financial Toxicity Impacts Cancer Patients

The term financial toxicity is relatively new and is being used to draw parallels between the physical toxicities of chemotherapy and the cost-related burdens cancer patients face.

January 28th 2015

Screening Does Not Save Lives Except in Very Few Exceptions

Laura Joszt, MA

Screening for deadly illnesses does not necessarily save lives despite assumptions otherwise, according to a study published in the International Journal of Epidemiology.

Two Years In: The Impact of the ACA on Oncology

January 28th 2015

Two Years In: The Impact of the ACA on Oncology

Although the Affordable Care Act (ACA) was signed into law more than 4 years ago, many aspects of it are fairly new, which makes it difficult to analyze the impact the law has had on the United States healthcare system.

January 28th 2015

Pharma Expects Push-Back on Cancer Drug Costs

After Steven Miller, CMO at Express Scripts, announced last week that his company would like to influence the oncology market, Pharma seems to have paid heed.

January 28th 2015

Study Shows Targeted Biopsy Better Than Standard Biopsy, in Prostate Cancer

Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a large-scale study.

Segment 2: Buyer Beware in the Diagnostic Test Market

January 27th 2015

Segment 2: Buyer Beware in the Diagnostic Test Market

There are currently 2 ways diagnostic tests can make it to market in the US: either through the FDA or laboratory-developed tests. This dual-pathway situation has led to a "buyer beware" market, according to Daniel F. Hayes, MD.

...

139 140 141 142 143 144 145 146 147

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions